By Leo Fasciocco, Ticker Tape Digest

Celgene (CELG) produces drugs to treat cancer and immune-inflammatory-​related diseases. Its primary commercial-stage products include Revlimid, Vidaza, Thalomid and Abraxande.

Technically, the long-term chart shows the stock soaring from 5 back in 2003 to a peak of 77 in 2008. The stock has now regrouped and is pushing once again toward its breakout point.

Annual revenues are $4.8 billion. It also has licensing deals with Novartis and has been active in making acquisitions.

For 2012, analysts forecast a 29% jump in CELG's earnings to $4.41 a share from $3.43 a year ago. The stock sells with a price-earnings ratio of 17. We see that as low making the stock a good value-growth play.

Net for the upcoming first quarter should soar 45% to $1.03 a share from 71 cents a year ago. The highest estimate on the Street is at $1.12 a share.

We see chances for an upside surprise. In the prior quarter, CELG topped the consensus estimate by 2 cents a share and the quarter before that by 11 cents a share.

Looking out to 2013, Wall Street projects an 18% gain in net to $5.18 a share from the anticipated $4.41 this year.

The accumulatio /distribution line is in an uptrend and is showing strong buying. That bodes well for a breakout to a new all-time high.

Buying can be done on the stock's move over $75.10. From there, we are targeting CELG for a move to $90. A protective stop can be placed near $71.

Insider activity is bullish. Insiders have been selective buyers of the stock in recent months. Their latest buys have come around $61.

Institutional sponsorship is excellent. A key fund buyer recently was 4-star rated Fidelity Contrafund which purchased 528,200 shares. Also, 4-star rated Harbor Capital Appreciation Fund was a recent buyer of 162,946 shares.

Related articles:

• Isis Pharmaceutical: Antisense profits
• Triple play in personalized medicine
• Ready for Reddy's